Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE, Inc. (BIOL) generates frequent news as a medical device company focused on dental laser systems for dentistry and medicine. Company announcements describe BIOLASE as a global or globally recognized leader in dental laser technology, with principal products that include dental laser systems used for cosmetic and complex surgical procedures and related consumables such as disposable tips. News coverage often highlights how its laser platforms aim to provide less pain and faster recovery times for patients, while supporting a wide range of dental disciplines.
Investors and dental professionals following BIOLASE news will see updates on product launches, clinical education initiatives, financial performance, capital markets developments, and corporate restructuring events. Recent releases have covered the launch of the Waterlase iPlus Premier Edition all‑tissue laser system, featuring modular software design, enhanced user interface, on‑board animations, and Wi‑Fi‑enabled remote diagnostics. BIOLASE news also includes information on educational programs such as the “Let’s Talk Dental” webinar series and the Waterlase and Epic Diode academies, which address topics across restorative dentistry, periodontics, endodontics, pediatric dentistry, dental hygiene, and practice management.
Financial and corporate news items provide detail on quarterly and full‑year results, trends in laser and consumables revenue, gross margin, operating expenses, and the use of non‑GAAP measures such as Adjusted EBITDA. In 2024, BIOLASE announced its delisting from The Nasdaq Stock Market and subsequent trading on OTC Markets, as well as voluntary Chapter 11 proceedings and a proposed sale of substantially all assets to Sonendo Inc. For users tracking BIOL stock and BIOLASE developments, this news page offers a centralized view of the company’s operational updates, product milestones, financial disclosures, and restructuring process over time.
BIOLASE (NASDAQ:BIOL) will participate in the 2025 Greater New York Dental Meeting (GNYDM) in New York City, November 28–December 3, 2025.
On Sunday, November 30, 2025, 10:00 AM–12:30 PM, Philip Kang, DDS, will present “Advancing Laser Solutions for Periodontal and Implant Health” on the GNYDM Main Stage for 3 CE credits, focusing on Er,Cr:YSGG (YSGG) laser technology, clinical advantages, patient comfort, and practice growth.
Visit Booth #4129 for hands-on demos of Waterlase iPlus and exclusive show-only pricing.
BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, has voluntarily initiated Chapter 11 proceedings in the United States Bankruptcy Court for the District of Delaware. The company is pursuing a sale process under Section 363 of the Bankruptcy Code and has entered into an asset purchase agreement with Sonendo Inc. for $14.0 million in cash, subject to conditions.
BIOLASE will seek Court approval to continue operating during the proceedings. The company has received a commitment from SWK Funding for no less than $2.5 million in Debtor-in-Possession (DIP) financing, including a $1.43 million interim advance, to maintain business operations. SSG Capital Advisors, has been engaged to advise on strategic options, including potential asset sales.
BIOLASE (NASDAQ:BIOL) reported its Q2 2024 financial results, highlighting a 40% gross margin, up from 33% in Q1 2024. The company achieved its second-highest consumable revenue ever, with over 600 recurring subscriptions. Net revenue was $11.6 million, down from $14.3 million in Q2 2023. U.S. laser revenue decreased to $3.6 million from $6.3 million year-over-year. Operating loss improved by 17% to $3.2 million. Net loss was $2.8 million or $0.08 per share, compared to $14.2 million or $26.14 per share in Q2 2023. Adjusted EBITDA loss was $2.5 million. BIOLASE updated its 2024 guidance, expecting full-year revenue similar to 2023 and an Adjusted EBITDA loss between $6-8 million.
BIOLASE, a leader in dental lasers, announced its delisting from Nasdaq due to non-compliance with listing requirements, such as maintaining a $1.00 minimum bid price and $2.5 million in stockholders' equity. Trading on Nasdaq will halt on June 20, 2024. CEO John Beaver emphasized that despite this setback, BIOLASE remains committed to expanding laser adoption in dental care. The company's stock will start trading on the OTC Markets Group platform under the symbol "BIOL" and aims to move to the OTCQB Market shortly.
Biolase (NASDAQ: BIOL) reported its Q1 2024 results, with increased adoption of dental lasers and a reiterated full-year guidance for revenue growth and profitability.
Key highlights include:
- 67% of U.S. Waterlase sales from new customers and 42% from dental specialists.
- Consumables sales up 14% year over year, marking the third strongest quarter.
- Gross margin improved by 1% year over year to 33%, with a 7% sequential increase.
- Adjusted EBITDA loss reduced by 21% year over year.
Full-year 2024 guidance expects net revenue growth of 6%-8%, totaling $52M-$53M, and positive Adjusted EBITDA. Despite a 3% decline in Q1 net revenue to $10.1M, expenses were cut by 9%, reducing the operating loss by 15%.
U.S. laser revenue fell 22%, while consumable revenue grew 17%. International laser revenue dropped 12%, but consumables rose 8%. Net loss for Q1 was $6.5M, or $0.36 per share.
BIOLASE, Inc. (NASDAQ:BIOL) will release its first quarter 2024 financial and operating results on May 13, 2024. The company will host a conference call and webcast to discuss the results and corporate developments. Investors can access the live call and archived webcast on the BIOLASE Investor Relations Page.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
